Foralumab nasal spray, an experimental therapy by Tiziana Life Sciences that’s being tested for multiple sclerosis and…
Articles by Margarida Maia, PhD
An upcoming observational clinical trial will assess how adherence to treatment with the portable neuromodulation stimulator (PoNS) device, used…
A group of four patients have entered a special program where they’ll gain access to foralumab nasal spray, an…
A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus…
Four weeks of treatment with nabiximols — an oral spray containing compounds found in the cannabis plant — significantly reduced…
A research team at Marquette University has received a $3.34 million grant from the National Institutes of Health (NIH) to test…
The presence of iron rim lesions, which are regions of chronic inflammation seen on MRI scans, may be linked to…
Three months of once-weekly sessions of high-intensity resistance training — consisting of strength exercises followed by a short recovery between…
The Accelerated Cure Project (ACP) for multiple sclerosis (MS) is teaming up with Quest Diagnostics to study…
A machine learning approach based on eye scans was employed by researchers to diagnose multiple sclerosis (MS) in children…
The first symptoms of relapsing-remitting multiple sclerosis (RRMS) have been appearing increasingly later in life, according to a Spanish…
The U.S. Food and Drug Administration (FDA) has agreed to review an application requesting that Polpharma Biologics‘ natalizumab, a…
Note: This story was updated July 20, 2022, to correct the headline to reflect that Soliris might be a…
Black Americans with multiple sclerosis (MS) have a higher chance of having uncontrolled…
Higher numbers of immune cells circulating in the bloodstream may mean a greater likelihood of developing multiple sclerosis (MS),…
Dysport (abobotulinumtoxinA), a form of purified botulinum toxin, has received a positive opinion in Europe for managing urinary incontinence…
Women who were exposed to sexual or emotional abuse as children may be at an increased risk of developing multiple sclerosis…
This year’s Scientific Breakthrough Award, funded by the American Brain Foundation, has been awarded to Stephen Hauser, MD, for…
COVID-19 does not seem to be linked to increased disability worsening or more relapses in the long term for people…
A researcher in Barcelona, Spain, has been chosen to receive the 2022 John Dystel Prize for his work advancing…
PIPE-307, an investigational myelin-restoring medication being developed by Pipeline Therapeutics for the treatment of multiple sclerosis (MS), appears…
Treatment with an autologous hematopoietic stem cell transplant (aHSCT) seems to reboot the immune system in multiple sclerosis (MS)…
This year’s Harry Weaver Neuroscience Scholar Award, funded by the National Multiple Sclerosis (MS) Society, has gone to a…
Tevogen Bio is planning to make use of its virus-fighting immune cell technology and turn it against Epstein-Barr virus…
Tecfidera (dimethyl fumarate) appears to have similar benefits to Gilenya (fingolimod) in preventing relapses and the loss of…
Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS),…
Cognition-targeting exercise, when combined with cognitive behavioral therapy (CBT) — a type of talk therapy — may further ease fatigue…
Donations to the Multiple Sclerosis Society of Canada through the end of this year will be double matched, meaning…
People with a higher genetic risk for multiple sclerosis (MS) are significantly more likely to develop the disease at…
Cortrophin Gel (repository corticotropin injection), an injectable gel medication approved for acute flares in multiple sclerosis (MS) and…